Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

WATERTOWN, Mass., Sept. 11, 2023 -- Werewolf Therapeutics, Inc. , an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate...

Related Keywords

Josh Rappaport ,Michaelb Atkins ,Williamm Scholl ,Michael Atkins ,Ellen Lubman ,Division Of Hematology Oncology ,Advisory Committee ,Lombardi Immunotherapy Initiative ,Werewolf Therapeutics Inc ,Beth Israel Deaconess Medical Center ,Globenewswire Inc ,Scientific Advisory Council ,Georgetown University ,Company Or Werewolf Nasdaq ,Harvard Medical School ,Scientific Communications ,Tufts Medical Center ,Division Of Hematology ,Georgetown Lombardi Comprehensive Cancer Center ,Medstar Georgetown University Hospital ,Chair Of The Melanoma Research Foundation ,Department Of Oncology ,Society For Immunotherapy Of Cancer ,Vice Chair ,Medical Center ,Israel Deaconess Medical Center ,Medical School ,Deputy Chief ,Biologic Therapy ,Cutaneous Oncology Programs ,Harvard Skin Cancer ,Harvard Cancer Center Kidney Program ,Deputy Director ,Lombardi Comprehensive Cancer Center ,Star Georgetown University ,Institutional Pilot Grants ,Melanoma Research Foundation ,Advisory Council ,Cancer Care ,Markets ,